A slew of ASX listed biotech and critical minerals names could lose millions due to changes in R&D incentives that have sparked concerns across the wider innovation community.
CSL
ASX:CSL
CSL faces investor backlash over delayed guidance reset.
The biotech giant delivered a hammer blow of a guidance downgrade on Monday morning. Shareholders wanted it three months ago.
Analysts are concerned the fumbled announcement of McKenzie’s abrupt departure the night before CSL’s first-half result may be an ominous sign.
Shareholder revolts, board spills and bonus battles — Australia’s AGM season has turned bloody, with James Hardie leading a wave of corporate reckonings.
CSL’s AGM turned fiery as shareholders raged over pay and profits, as plunging vaccination rates batter the biotech’s bottom line.
CSL chief executive Paul McKenzie has been called out for selling millions of dollars in shares in a torrid year for the ailing biotech giant.
ASX biotech stocks rebounded en masse on Monday but there are still concerns Donald Trump's pharma tariffs will cast a shadow over the sector.
CSL’s sweeping restructure has hammered its share price, but the Allan Gray chief investment officer says the shift may finally make the biotech a buy.
This earnings season was defined by "once in a generation" swings in the share prices of some of the bluest of blue-chip names on the ASX. The jury's still out on what's driving it.
The final week of earnings season promises more surprise punches as CSL and James Hardie feel the pain of their US exposures.
The cuts and restructures at CSL show the risks of relying on a few large players to carry Australia’s research and innovation forward.
CSL’s $20 billion wipeout after a shock restructure announcement dragged the ASX lower, as investors punished the biotech with its steepest fall in six years.
Shares in the biotech giant plunged today after a sharp sales decline in its immunisation business in the US, where vaccine-sceptic Robert F Kennedy Jr is set to become health secretary.
